Spots Global Cancer Trial Database for ezabenlimab
Every month we try and update this database with for ezabenlimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) | NCT04958239 | Neoplasms | BI 765179 Ezabenlimab | 18 Years - | Boehringer Ingelheim | |
| A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface | NCT04752215 | Colorectal Neop... | BI 765049 ezabenlimab | 18 Years - | Boehringer Ingelheim | |
| A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | NCT05879978 | Small Cell Lung... Neuroendocrine ... | BI 764532 Ezabenlimab | 18 Years - | Boehringer Ingelheim | |
| A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery | NCT05446129 | Colorectal Canc... | Ezabenlimab BI 765063 Pembrolizumab | 18 Years - | Boehringer Ingelheim | |
| A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) | NCT04958239 | Neoplasms | BI 765179 Ezabenlimab | 18 Years - | Boehringer Ingelheim | |
| A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours | NCT03468426 | Non-squamous, N... Neoplasms | BI 836880 ezabenlimab | 18 Years - | Boehringer Ingelheim | |
| A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer | NCT05249426 | Head and Neck S... | BI 765063 Ezabenlimab BI 836880 Cetuximab Investigator´s ... | 18 Years - | Boehringer Ingelheim | |
| A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab | NCT05068102 | Carcinoma, Squa... Melanoma Non-small Cell ... | BI 765063 Ezabenlimab [89Zr]Zr- BI 76... BI 770371 [89Zr]Zr- BI 77... | 18 Years - | Boehringer Ingelheim | |
| A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 | NCT06091930 | Gastrointestina... Lung Cancer Pancreatic Canc... Colorectal Canc... Head and Neck C... Liver Cancer | BI 765049 Ezabenlimab | 18 Years - | Boehringer Ingelheim | |
| A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface | NCT04752215 | Colorectal Neop... | BI 765049 ezabenlimab | 18 Years - | Boehringer Ingelheim | |
| A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery | NCT05446129 | Colorectal Canc... | Ezabenlimab BI 765063 Pembrolizumab | 18 Years - | Boehringer Ingelheim | |
| Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma | NCT06370871 | Advanced Soft T... Undifferentiate... Myxofibrosarcom... | Brigimadlin Ezabenlimab Gemcitabine Docetaxel | 18 Years - | Boehringer Ingelheim | |
| A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours) | NCT05471856 | Solid Tumors | BI 1703880 Ezabenlimab | 18 Years - | Boehringer Ingelheim |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
